FINAL REGISTRATION REPORT

Part B

Section 10

Assessment of the relevance of metabolites in groundwater

Detailed summary of the risk assessment

Product code: SHA 6100 A

Product name: ALIVE

Chemical active substance:

Propaquizafop, 100 g/L

Central Zone

Zonal Rapporteur Member State: Poland

CORE ASSESSMENT

Applicant: Sharda Cropchem España S.L.

Submission date: October 2020

MS Finalisation date: 03/2021; 03/2022

Version history

When	What
March 2021	ZRMS evaluated the dRR
March 2022	The Final Registration Report

Table of Contents

10 Relevance of metabolites in groundwater

10.1 General information

The metabolites Quizalofop, Hydroxy-quizalofop, Dihydroxy-quinoxaline, Hydroxy-quinoxaline are predicted to occur in groundwater at concentrations below 0.001 µg/L (see chapter 8.8 of section B8 Environmental Fate). Assessment of the relevance of these metabolites according to the stepwise procedure of the EC guidance document SANCO/221/2000 –rev.10 is therefore not required.

General information on the metabolites is provided in Table 10.1-1. The impact of the relevance assessment on whether a particular GAP use leads to acceptable risk or not is presented in the summary of the cGAP evaluation in chapter 8.8 of the dRR Part B, Section 8 (Environmental fate and behaviour).

Table 10.1-1: General information on the metabolite(s)

Name of active substance	Metabolite name and code	Structural/molecular formula	Trigger for relevance assessmnent	
Propaquizafop	Quizalofop		Max PEC_{gw} Based on:	< 0.001 µg/L FOCUS PEARL and PELMO (all scenarios)
	Hydroxy quizalofop	 # chiral centre	Max PEC_{gw} Based on:	< 0.001 µg/L FOCUS PEARL and PELMO (all scenarios)
	Dihydroxy-quinoxaline		Max PECgw Based on:	< 0.001 µg/L FOCUS PEARL and PELMO (all scenarios)
	Hydroxy-quinoxaline		Max PECgw Based on:	< 0.001 µg/L FOCUS PEARL and PELMO (all scenarios)

10.2 Relevance assessment of metabolites Quizalofop, Hydroxy-quizalofop, Dihydroxy-quinoxaline, Hydroxy-quinoxaline

Not required, please refer to point 10.1.

10.2.1 STEP 1: Exclusion of degradation products of no concern

Not required, please refer to point 10.1.

10.2.2 STEP 2: Quantification of potential groundwater contamination

Not required, please refer to point 10.1.

10.2.3 STEP 3: Hazard assessment – identification of relevant metabolites

Not required, please refer to point 10.1.

10.2.4 STEP 4: Exposure assessment – threshold of concern approach

Not required, please refer to point 10.1.

10.2.5 STEP 5: Refined risk assessment

Not required, please refer to point 10.1

The metabolites Quizalofop, Hydroxy-quizalofop, Dihydroxy-quinoxaline, Hydroxy-quinoxaline are predicted to occur in groundwater at concentrations below 0.001 µg/L and then assessment of the relevance of these metabolites according to the stepwise procedure of the EC guidance document SANCO/221/2000 –rev.10 is therefore not required.
According to the EFSA Scientific Report (2008) 204, 1-171 propaquizafop is extensively metabolised. Major metabolites are the free acid of the parent compound and further oxidation products